We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
ASH Q1 Earnings Beat, Sales Miss on Avoca Divestiture, Weak Demand
Read MoreHide Full Article
Key Takeaways
ASH posted a Q1 2026 loss of $14M, narrower year over year, while sales declined 5% to $386M.
ASH sales hit by Avoca divestiture and weak demand in coatings, construction, personal care and industrials.
ASH forecasts 2026 sales of $1.835-$1.905B and adjusted EBITDA of $400-$420M on operating improvements.
Ashland Global Holdings Inc. (ASH - Free Report) recorded a loss from continuing operations of $14 million or 30 cents per share for the first quarter of fiscal 2026 (ended Dec. 31, 2025) compared with a loss of $166 million or $3.51 per share in the prior-year quarter.
Barring one-time items, adjusted earnings were 26 cents per share, down from the year-ago quarter figure of 28 cents. The bottom line beat the Zacks Consensus Estimate of 23 cents.
Sales were down 5% year over year to $386 million. The top line missed the Zacks Consensus Estimate of $408.3 million. Sales for the first quarter were adversely impacted by the divestiture of its Avoca business, which reduced revenue by roughly $10 million, and softer demand in certain end-markets like coatings, construction, personal care and industrial, along with modest pricing pressure.
Life Sciences: Sales in the segment were up 4% year over year to $139 million in the reported quarter. The Zacks Consensus Estimate for the same was $146 million. The year-over-year rise was primarily driven by higher sales volumes within pharma applications, where demand remained resilient.
Personal Care: Sales in the division declined 8% year over year to $123 million. The metric fell short of the Zacks Consensus Estimate of $132 million. The decrease was primarily due to portfolio optimization, mainly attributed to the divestiture of the Avoca business line.
Specialty Additives: Sales in the segment fell 11% year over year to $102 million and missed the Zacks Consensus Estimate of $111 million. The decline was primarily due to the weak coatings demand in China, tougher competition across MEAI, softer North America demand and continued slowdown in global architectural coatings and construction markets.
Intermediates: Sales in the segment went down 6% year over year to $31 million. The figure beat the consensus estimate of $30.26 million. Overall sales decreased, mostly due to lower pricing across the BDO value chain amid a persistently oversupplied market.
ASH’s Financials
Cash and cash equivalents were $304 million at the end of the quarter, up around 41.4% sequentially. Long-term debt was $1,387 million, up roughly 0.2% from the prior quarter.
ASH’s Outlook
For fiscal 2026, Ashland expects sales to be in the range of $1.835-$1.905 billion and adjusted EBITDA to be $400-$420 million. Adjusted EPS, excluding intangible amortization, is forecast to deliver double-digit-plus growth on operating improvements and portfolio optimization, while free cash flow conversion is targeted at roughly 50% of adjusted EBITDA, with capital expenditure of about $100 million.
ASH’s Price Performance
Shares of Ashland are down 4.5% in the past year compared with a 1% decline in the industry.
Image Source: Zacks Investment Research
ASH’s Zacks Rank & Key Picks
ASH currently carries a Zacks Rank #4 (Sell).
Some better-ranked stocks worth a look in the basic materials space are Sociedad Quimica y Minera de Chile S.A. (SQM - Free Report) , AngloGold Ashanti plc (AU - Free Report) , and Methanex Corporation (MEOH - Free Report) .
Sociedad is expected to report fourth-quarter results on Feb. 27. SQM sports a Zacks Rank #1 (Strong Buy) at present. The Zacks Consensus Estimate for SQM’s fourth-quarter earnings is pegged at 75 cents, indicating 79% year-over-year growth. You can see the complete list of today’s Zacks #1 Rank stocks here.
AngloGold is scheduled to report fourth-quarter results on Feb. 20. AU carries a Zacks Rank #1 at present. The consensus estimate for AU’s fourth-quarter earnings is pegged at $1.9 per share, indicating 113.5% year-over-year growth.
Methanex is scheduled to report fourth-quarter results on Mar. 5. MEOH carries a Zacks Rank #2 (Buy) at present. The Zacks Consensus Estimate for MEOH’s fourth-quarter earnings is pegged at 81 cents per share, indicating a 35% year-over-year decline.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
ASH Q1 Earnings Beat, Sales Miss on Avoca Divestiture, Weak Demand
Key Takeaways
Ashland Global Holdings Inc. (ASH - Free Report) recorded a loss from continuing operations of $14 million or 30 cents per share for the first quarter of fiscal 2026 (ended Dec. 31, 2025) compared with a loss of $166 million or $3.51 per share in the prior-year quarter.
Barring one-time items, adjusted earnings were 26 cents per share, down from the year-ago quarter figure of 28 cents. The bottom line beat the Zacks Consensus Estimate of 23 cents.
Sales were down 5% year over year to $386 million. The top line missed the Zacks Consensus Estimate of $408.3 million. Sales for the first quarter were adversely impacted by the divestiture of its Avoca business, which reduced revenue by roughly $10 million, and softer demand in certain end-markets like coatings, construction, personal care and industrial, along with modest pricing pressure.
Ashland Inc. Price, Consensus and EPS Surprise
Ashland Inc. price-consensus-eps-surprise-chart | Ashland Inc. Quote
ASH’s Segment Highlights
Life Sciences: Sales in the segment were up 4% year over year to $139 million in the reported quarter. The Zacks Consensus Estimate for the same was $146 million. The year-over-year rise was primarily driven by higher sales volumes within pharma applications, where demand remained resilient.
Personal Care: Sales in the division declined 8% year over year to $123 million. The metric fell short of the Zacks Consensus Estimate of $132 million. The decrease was primarily due to portfolio optimization, mainly attributed to the divestiture of the Avoca business line.
Specialty Additives: Sales in the segment fell 11% year over year to $102 million and missed the Zacks Consensus Estimate of $111 million. The decline was primarily due to the weak coatings demand in China, tougher competition across MEAI, softer North America demand and continued slowdown in global architectural coatings and construction markets.
Intermediates: Sales in the segment went down 6% year over year to $31 million. The figure beat the consensus estimate of $30.26 million. Overall sales decreased, mostly due to lower pricing across the BDO value chain amid a persistently oversupplied market.
ASH’s Financials
Cash and cash equivalents were $304 million at the end of the quarter, up around 41.4% sequentially. Long-term debt was $1,387 million, up roughly 0.2% from the prior quarter.
ASH’s Outlook
For fiscal 2026, Ashland expects sales to be in the range of $1.835-$1.905 billion and adjusted EBITDA to be $400-$420 million. Adjusted EPS, excluding intangible amortization, is forecast to deliver double-digit-plus growth on operating improvements and portfolio optimization, while free cash flow conversion is targeted at roughly 50% of adjusted EBITDA, with capital expenditure of about $100 million.
ASH’s Price Performance
Shares of Ashland are down 4.5% in the past year compared with a 1% decline in the industry.
ASH’s Zacks Rank & Key Picks
ASH currently carries a Zacks Rank #4 (Sell).
Some better-ranked stocks worth a look in the basic materials space are Sociedad Quimica y Minera de Chile S.A. (SQM - Free Report) , AngloGold Ashanti plc (AU - Free Report) , and Methanex Corporation (MEOH - Free Report) .
Sociedad is expected to report fourth-quarter results on Feb. 27. SQM sports a Zacks Rank #1 (Strong Buy) at present. The Zacks Consensus Estimate for SQM’s fourth-quarter earnings is pegged at 75 cents, indicating 79% year-over-year growth. You can see the complete list of today’s Zacks #1 Rank stocks here.
AngloGold is scheduled to report fourth-quarter results on Feb. 20. AU carries a Zacks Rank #1 at present. The consensus estimate for AU’s fourth-quarter earnings is pegged at $1.9 per share, indicating 113.5% year-over-year growth.
Methanex is scheduled to report fourth-quarter results on Mar. 5. MEOH carries a Zacks Rank #2 (Buy) at present. The Zacks Consensus Estimate for MEOH’s fourth-quarter earnings is pegged at 81 cents per share, indicating a 35% year-over-year decline.